Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03453619 |
|
Recruitment Status : Unknown
Verified August 2020 by Apellis Pharmaceuticals, Inc..
Recruitment status was: Active, not recruiting
First Posted : March 5, 2018
Last Update Posted : September 2, 2020
|
Sponsor:
Apellis Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Actual Primary Completion Date : | April 16, 2020 |
| Estimated Study Completion Date : | December 2022 |
| Certification/Extension First Submitted : | August 27, 2020 |